(OHI) Omega Healthcare Investors - Overview
Stock: Skilled Nursing, Assisted Living, Care Homes, Healthcare REIT
| Risk 5d forecast | |
|---|---|
| Volatility | 20.5% |
| Relative Tail Risk | -3.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.44 |
| Alpha | 33.41 |
| Character TTM | |
|---|---|
| Beta | 0.100 |
| Beta Downside | 0.085 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.47% |
| CAGR/Max DD | 1.93 |
EPS (Earnings per Share)
Revenue
Description: OHI Omega Healthcare Investors January 03, 2026
Omega Healthcare Investors (NYSE: OHI) is a publicly-traded REIT that finances and owns long-term care properties-primarily skilled-nursing and assisted-living facilities-in the United States and the United Kingdom. As of the most recent quarter (Sept 30 2025) the portfolio comprises 1,024 operating sites across 42 U.S. states, D.C., and the U.K./Jersey (including 290 U.K. care homes), managed by 88 distinct operators, plus an additional 19 facilities held through unconsolidated entities. The REIT’s stated objective is to acquire “quality” healthcare assets with strong operators to maximize a favorable risk-adjusted return for shareholders.
Key quantitative signals (as of Q3 2025) include a weighted-average lease-expiry horizon of 7.2 years, an occupancy-adjusted net operating income (NOI) margin of roughly 38 %, and a dividend yield near 6.5 %-both above the median for Health Care REITs. The sector’s fundamentals are driven by demographic aging (U.S. Medicare-eligible population projected to rise 10 % by 2030) and constrained supply of skilled-nursing beds, which historically supports rent-growth rates of 2-3 % annually. However, operator credit risk and regulatory reimbursement changes remain material uncertainties that could compress yields.
For a deeper, data-rich view of OHI’s valuation dynamics, you may find ValueRay’s interactive dashboards useful.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 590.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: 122.7% < 20% (prev 219.6%; Δ -96.87% < -1%) |
| CFO/TA 0.09 > 3% & CFO 879.7m > Net Income 590.1m |
| Net Debt (4.23b) to EBITDA (1.17b): 3.62 < 3 |
| Current Ratio: 3.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (313.2m) vs 12m ago 8.97% < -2% |
| Gross Margin: 84.91% > 18% (prev 0.99%; Δ 8393 % > 0.5%) |
| Asset Turnover: 11.96% > 50% (prev 10.62%; Δ 1.34% > 0%) |
| Interest Coverage Ratio: 3.92 > 6 (EBITDA TTM 1.17b / Interest Expense TTM 215.1m) |
Altman Z'' -0.45
| A: 0.15 (Total Current Assets 2.06b - Total Current Liabilities 594.5m) / Total Assets 10.05b |
| B: -0.36 (Retained Earnings -3.62b / Total Assets 10.05b) |
| C: 0.08 (EBIT TTM 842.4m / Avg Total Assets 9.97b) |
| D: -0.76 (Book Value of Equity -3.51b / Total Liabilities 4.61b) |
| Altman-Z'' Score: -0.45 = B |
Beneish M -2.70
| DSRI: 0.87 (Receivables 2.00b/2.03b, Revenue 1.19b/1.05b) |
| GMI: 1.16 (GM 84.91% / 98.62%) |
| AQI: 1.38 (AQ_t 0.13 / AQ_t-1 0.09) |
| SGI: 1.13 (Revenue 1.19b / 1.05b) |
| TATA: -0.03 (NI 590.1m - CFO 879.7m) / TA 10.05b) |
| Beneish M-Score: -2.70 (Cap -4..+1) = A |
What is the price of OHI shares?
Over the past week, the price has changed by -1.75%, over one month by +4.95%, over three months by +6.01% and over the past year by +37.56%.
Is OHI a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.4 | 3.9% |
| Analysts Target Price | 48.4 | 3.9% |
OHI Fundamental Data Overview February 21, 2026
P/E Forward = 10.1317
P/S = 11.8771
P/B = 2.704
P/EG = 1.13
Revenue TTM = 1.19b USD
EBIT TTM = 842.4m USD
EBITDA TTM = 1.17b USD
Long Term Debt = 4.26b USD (from longTermDebt, last quarter)
Short Term Debt = 242.0m USD (from shortTermDebt, last quarter)
Debt = 4.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.23b USD (from netDebt column, last quarter)
Enterprise Value = 18.36b USD (14.13b + Debt 4.26b - CCE 27.0m)
Interest Coverage Ratio = 3.92 (Ebit TTM 842.4m / Interest Expense TTM 215.1m)
EV/FCF = 21.36x (Enterprise Value 18.36b / FCF TTM 859.8m)
FCF Yield = 4.68% (FCF TTM 859.8m / Enterprise Value 18.36b)
FCF Margin = 72.09% (FCF TTM 859.8m / Revenue TTM 1.19b)
Net Margin = 49.47% (Net Income TTM 590.1m / Revenue TTM 1.19b)
Gross Margin = 84.91% ((Revenue TTM 1.19b - Cost of Revenue TTM 179.9m) / Revenue TTM)
Gross Margin QoQ = 47.22% (prev none%)
Tobins Q-Ratio = 1.83 (Enterprise Value 18.36b / Total Assets 10.05b)
Interest Expense / Debt = 1.22% (Interest Expense 51.8m / Debt 4.26b)
Taxrate = 1.22% (2.13m / 174.1m)
NOPAT = 832.1m (EBIT 842.4m * (1 - 1.22%))
Current Ratio = 3.46 (Total Current Assets 2.06b / Total Current Liabilities 594.5m)
Debt / Equity = 0.82 (Debt 4.26b / totalStockholderEquity, last quarter 5.18b)
Debt / EBITDA = 3.62 (Net Debt 4.23b / EBITDA 1.17b)
Debt / FCF = 4.92 (Net Debt 4.23b / FCF TTM 859.8m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.92% (Net Income 590.1m / Total Assets 10.05b)
RoE = 11.83% (Net Income TTM 590.1m / Total Stockholder Equity 4.99b)
RoCE = 9.11% (EBIT 842.4m / Capital Employed (Equity 4.99b + L.T.Debt 4.26b))
RoIC = 8.61% (NOPAT 832.1m / Invested Capital 9.66b)
WACC = 5.11% (E(14.13b)/V(18.39b) * Re(6.28%) + D(4.26b)/V(18.39b) * Rd(1.22%) * (1-Tc(0.01)))
Discount Rate = 6.28% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 10.49%
[DCF Debug] Terminal Value 86.91% ; FCFF base≈801.0m ; Y1≈850.5m ; Y5≈1.02b
Fair Price DCF = 87.48 (EV 30.09b - Net Debt 4.23b = Equity 25.86b / Shares 295.6m; r=5.90% [WACC]; 5y FCF grow 6.85% → 2.90% )
EPS Correlation: 31.00 | EPS CAGR: -9.20% | SUE: 0.65 | # QB: 0
Revenue Correlation: 64.92 | Revenue CAGR: 7.04% | SUE: 3.38 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.54 | Chg30d=+0.068 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.05 | Chg30d=+0.107 | Revisions Net=+1 | Growth EPS=+0.6% | Growth Revenue=+17.5%
EPS next Year (2027-12-31): EPS=2.10 | Chg30d=+0.108 | Revisions Net=+1 | Growth EPS=+2.8% | Growth Revenue=+3.3%